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The recent development and regulatory approval of a variety of serological assays indicating the presence of antibodies against se-
vere acute respiratory syndrome coronavirus 2 has led to rapid and widespread implementation of seroprevalence studies. Accurate 
estimates of seroprevalence are needed to model transmission dynamics and estimate mortality rates. Furthermore, seropreva-
lence levels in a population help guide policy surrounding reopening efforts. The literature to date has focused heavily on issues 
surrounding the quality of seroprevalence tests and less on the sampling methods that ultimately drive the representativeness of 
resulting estimates. Seroprevalence studies based on convenience samples are being reported widely and extrapolated to larger popu-
lations for the estimation of total coronavirus disease 2019 (COVID-19) infections, comparisons of prevalence across geographic 
regions, and estimation of mortality rates. In this viewpoint, we discuss the pitfalls that can arise with the use of convenience samples 
and offer guidance for moving towards more representative and timely population estimates of COVID-19 seroprevalence.
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LIMITATIONS TO THE 
GENERALIZABILITY OF EARLY 
SEVERE ACUTE RESPIRATORY 
SYNDROME CORONAVIRUS 2 
SEROPREVALENCE STUDIES
In addition to direct health impacts, co-
ronavirus disease 2019 (COVID-19) 
has caused an unprecedented level of 
disruption to social networks and ec-
onomic systems. Phased “re-opening” 
policies are being guided by surrogate 
measures of severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) 
transmission, including symptom-based 
(ie, syndromic surveillance), test-based 
(ie, positivity rates), and facility-based 
(ie, hospitalizations) measures of dis-
ease activity [1]. The United States has 
experienced shortages of critical testing 
supplies, which has contributed to an 
underreporting of cases and struggling 
mitigation efforts [2]. Given the per-
sistent issues, many individuals face ac-
cessing testing and the high proportion of 
subclinical infections that do not prompt 
care-seeking [3, 4], these metrics are sub-
optimal measures of disease activity in 
the community.
The recent development and rapid 
regulatory approval of serological assays 
indicating the presence of antibodies 
against SARS-CoV-2 has led to wide-
spread implementation of seroprevalence 
studies [5]. These studies have used a wide 
range of assays and recruitment methods. 
Although issues surrounding test per-
formance have been the focus of much 
debate [6], there has been much less dis-
cussion around the rigor and appropri-
ateness of sampling frames. In this study, 
we illustrate some of the pitfalls associ-
ated with the use of convenience samples 
and provide guidance on best practices 
for quickly generating population-based 
estimates of seroprevalence.
To date, several large seroprevalence 
studies have been published in both the 
preprint and peer-reviewed literature. 
The majority of these studies have used 
convenience sampling, with participants 
recruited from online platforms (eg, 
Facebook), healthcare facilities, market 
research databases, or shopping cen-
ters [7–10]. The benefit of convenience 
sampling is that recruitment can occur 
relatively quickly and it is generally less 
expensive than probability-based sam-
pling approaches. The major disadvan-
tage is that resulting estimates will often 
not reflect the true seroprevalence in the 
underlying population due to selection 
bias. That is, recruitment methods and 
inherent factors that drive participation 
in convenience samples often lead to 
samples that do not reflect the underlying 
population in terms of demographic 
composition and risk factors for COVID-
19 infection. Moreover, it is very difficult 
to estimate the level of bias introduced by 
convenience sampling, especially when 
there are few population-based studies 
available for comparison. This can make 
applyparastyle “fig//caption/p[1]” parastyle “FigCapt”
extrapolation to underlying popula-
tions and estimation of mortality rates 
problematic.
Selection bias inherent in convenience 
samples is largely a result of competing 
factors that may influence an individual’s 
participation. For example, an individual 
with a prior COVID-19 infection might 
be more likely to volunteer for a sero-
prevalence study due to recent symptoms 
compared with someone without a prior 
infection who has been asymptomatic, 
thus leading to an overestimate of sero-
prevalence in the underlying population. 
Likewise, persons in shopping centers 
and other public areas where recruitment 
occurs may be at higher risk for COVID-
19 than the general population. In con-
trast, persons who are avoiding shopping 
centers, perhaps due to underlying illness 
or the presence of high-risk individuals 
in the household, are essentially excluded 
from participating in seroprevalence 
studies with this recruitment method. 
Other design features of convenience 
samples can result in underestimating 
seroprevalence. Studies based on social 
media recruitment have reported under-
representation of older persons and over-
representation of non-Hispanic whites 
[8]. However, African American and 
Hispanic populations have been dispro-
portionally impacted by the COVID-19 
pandemic [11]. Thus, underrepresenta-
tion in studies may not only contribute 
to underestimates of community sero-
prevalence but also to poorly targeted 
policy. Although weighting methods [8] 
or modeling approaches [12] can be used 
to improve representativeness of con-
venience samples, such methods rely on 
assumptions that cannot be validated. 
These methods typically assume that par-
ticipants are like a random sample from 
the population stratified by a known set 
of characteristics. When this assumption 
holds, these methods provide unbiased 
estimates. Violations occur when partic-
ipation is driven by the outcome itself or 
when participation and risk for the out-
come are driven by factors not accounted 
for in the analysis. This leaves researchers 
to speculate about how these errors offset 
one another and if the results are truly 
representative [8, 10].
To illustrate some of these biases, we 
examined characteristics of the under-
lying population for a seroprevalence 
study conducted in Santa Clara County, 
California in early April [8]. Participants 
were recruited using targeted Facebook 
advertisements and community listserves. 
Although researchers tried to recruit 
such that the distribution of participants 
would accurately reflect the population 
geographically, persons in wealthier areas 
were overrepresented. The sample also 
underrepresented men, persons 65 and 
older, Hispanics, and Asians. Researchers 
weighted the sample such that the 
weighted distributions of participants by 
ZIP Code, sex, and race/ethnicity would 
reflect known county demographics, and 
weighted estimates of seroprevalence 
were produced. This approach assumes 
that participants in the study are like a 
random sample of Santa Clara residents 
stratified by ZIP Code, sex, and race/eth-
nicity. There is some evidence to ques-
tion the validity of this assumption. Age, 
a factor correlated with COVID-19 risk 
[13], was not included as a weighting 
variable. Although 12.9% of Santa Clara 
residents are reported as being aged 65 or 
older, only 4.5% of the weighted sample 
represented this age group. Furthermore, 
characteristics such as occupation [14] 
and social distancing practices [15] are 
likely drivers of COVID-19 infection and 
were not accounted for in the weighting 
or analysis. The results of the Santa Clara 
study and other convenience samples 
have been publicized widely in the media 
[5, 7, 16], and thus the estimates from 
these studies have the potential to influ-
ence policymakers.
BEST PRACTICES FOR 
GENERATING A REPRESENTATIVE 
SAMPLING FRAME
Classic sample surveys achieve represen-
tation by ensuring that (1) all members of 
the population of interest have a chance of 
being included in the study, (2) members 
of the population are randomly selected 
for participation, and (3) researchers can 
quantify the chance that each sampled 
person was selected. These criteria are 
grounded in probability theory and have 
long been used to provide valid inference 
about target populations from concrete 
sampling frames, which are lists of pop-
ulation members from which samples 
are selected. Although sample surveys 
can suffer from generalizability concerns 
when there are problems with the sam-
pling frame or participation, these errors 
have long been recognized, and methods 
have been developed to minimize errors 
throughout the survey process [17].
Representative surveys of the general 
population are commonly based on sam-
pling frames constructed from lists of ad-
dresses or telephone numbers. If the goal 
of a research team is to estimate SARS-
CoV-2 seroprevalence within a popula-
tion residing in a single municipality, a 
representative estimate can be obtained 
using household sampling methods. 
Frasier et  al [18] propose a design for 
representative COVID-19 seropreva-
lence studies in the United States using 
address-based sampling (ABS) methods. 
With ABS, samples are randomly selected 
from lists of mailing addresses derived 
from the US Postal Services’ database 
[19]. Participants are recruited by mail 
or in-person for study participation, 
and testing is conducted in neighboring 
clinics or using self-administered test kits 
with at-home collection [18]. The ABS 
methodology has been validated in nu-
merous settings and geographies to have 
high coverage of the general population 
[19–21]. Because selection is random 
and not driven by the participant or the 
researcher, selection bias due to the sam-
pling method is eliminated. Guidance for 
sample size determination [18, 22] and 
the logistics of conducting seropreva-
lence studies using ABS [18] are available. 
Sampling techniques such as stratification 
and clustering can facilitate efficient de-
signs, logistic feasibility, and estimation 
of subpopulations of interest. Designs 
can incorporate oversampling of at-risk 
and vulnerable populations to allow for 
robust assessments of seroprevalence 
in these populations. The application of 
ABS methods to estimate SARS-CoV-2 
seroprevalence is new, so characteris-
tics of nonresponse are still unknown. 
Established methods to enhance com-
munity engagement as well as minimize, 
measure, and adjust for nonparticipation 
within the sample [17, 23] should be used 
to ensure that those who participate are 
representative of the target population.
Household sampling can be a time- 
and cost-intensive process. Because of 
the urgency to obtain seroprevalence es-
timates quickly, an efficient approach is 
to partner with an existing study already 
collecting representative data in the ge-
ography of interest. For example, we are 
working with a local health department 
that has an established household cohort 
for estimating factors related to popula-
tion health in the county. The sample for 
the cohort has been selected, and parti-
cipants have already been recruited to 
complete annual surveys. Representative 
estimates of seroprevalence will be 
obtained relatively quickly by recruiting 
within the existing study sample [24]. 
Likewise, researchers in Switzerland 
obtained representative estimates of se-
roprevalence by sampling former parti-
cipants from a representative survey of 
population health [25]. Collaboration 
between researchers across disciplines 
and institutions can facilitate these types 
of timely but representative estimates of 
seroprevalence.
CONCLUSIONS
Although they are more time-consuming 
and resource-intensive, representative 
samples are urgently needed to quan-
tify seroprevalence of COVID-19 and to 
monitor disease trends over time. These 
studies will also serve as benchmarks for 
evaluating the performance of less rig-
orous methodologies, including conven-
ience samples. Not all researchers can 
use probability-based sampling methods 
due to time and cost constraints. In 
these circumstances, estimates based on 
extrapolation from convenience samples 
should clearly outline the assumptions 
being made, and, when possible, results 
should be compared with benchmarks 
from probability-based studies. Although 
representative studies will take time, we 
caution against overinterpreting the results 
of convenience samples in the interim.
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